Korruption torjunta osana yritysvastuuta


Dittmar & Indreniuksen ja Terveysteknologia ry:n yhteistyössä toteuttaman webinaarisarjan kolmannessa osassa Juli Mansnérus ja Hanna-Mari Manninen puhuvat korruption torjunnan merkityksestä osana vastuullista yritystoimintaa.

Webinaarissa käsitellään muun muassa seuraavia aiheita:

  • Vastuullinen yritystoiminta ja korruption torjunta: Miksi se on tärkeää?
  • Mitä korruptio on?
  • Miten toimia käytännössä, ja onko Healthtech-yrityksillä jotakin erityistä huomioitavaa?

tiistai 17.5.2022, klo 10.00 – 11.00

Jos et ole saanut kutsua tilaisuuteen ja haluaisit osallistua, voit olla yhteydessä:
[email protected]

Tilaisuutemme ovat ensisijaisesti tarkoitettu asiakkaillemme ja muille sidosryhmillemme.

The webinar is in Finnish.

More by the same author

MiCA – Markets in Crypto-Assets regulation – What, why and when?

The European Commission adopted a legislative proposal on the regulation of crypto-assets as a part of the digital finance package in September 2020. This legislative proposal, Markets in Crypto-Assets (the “MiCA”) regulation, was approved by the European Council on 5 October 2022 and is currently pending the European Parliament’s approval. MiCA will address crypto-assets that are not currently governed by existing regulations, including utility tokens, asset-referenced tokens and e-money tokens, and establish a legal framework for crypto-asset services providers as well as consumer protection.

The European pharmaceuticals legislation in transition – Finnish perspectives

As part of the EU’s aim to create a stronger European Health Union, the European Commission (“Commission”) published a Pharmaceutical Strategy for the EU (“Strategy”) in November 2020. More recently, the COVID-19 pandemic has highlighted several shortcomings in the EU’s current pharmaceutical system and showed the vulnerability of global supply chains. The Commission now plans to review and revise the EU’s general legislation on medicines for human use to ensure “a future-proof and crisis-resistant medicines regulatory system”. Simultaneously, the Member States of the EU, such as Finland, are dealing with some severe challenges with the economic sustainability of their healthcare systems. We are now facing a true challenge – how to boost the pharmaceutical sector’s global competitiveness and create a regulatory environment, which is attractive for innovation and investment in an economically sustainable way?

Directive on corporate sustainability due diligence – What, who, and when?

The European Commission’s proposal for a Directive on Corporate Sustainability Due Diligence (the “Directive”) was published on 23 February 2022. The long-awaited Directive sets out a proposed EU standard for human rights and environmental due diligence. What is the proposed Directive about? Is your company within its scope? What do you need to do – and when?

Latest insights

Busy times ahead – Review of Finnish merger control in 2022

Alert / 24 Jan 2023
Reading time 6 minutes

D&I Transaction Powerhouse Deal Announcement

Alert / 19 Jan 2023
Reading time 2 minutes